In the February 2009 issue
Pre-clinical Cell based assays
Human Collagen Type I ELISA
Recent Peer Publications
Monoclonal antibody to Keratocan
Tools & strategies for investigating your novel therapies
On demand webcast: Pre-clinical cell based assays. Benefits and relationship with in vivo models.
Too many therapeutics continue to fail during middle to late stage development, while pressure to deliver new drugs increases. It is well recognized that the productivity in drug discovery has decreased in the past years despite an increase in R&D spending. In todays economic climate, every effort must be made to shorten this cycle and reduce spending and late stage failures. Cell based assays offer the potential to screen out compound failures in the discovery and development phase, contributing to an increased productivity.
During this 1-hour On-Demand webcast, we will discuss:
- Cost effective high throughput screening: evaluate a large number of compounds in a single system or screen one compound through a panel of assays prior to moving into in vivo models.
- Relationship between in vitro and in vivo models.
- Simplifying the system: following efficacy in an in vivo model, use a well defined in vitro model to determine mode of action.
- Case study for custom assays: by knowing the end goal, assays can be designed to evaluate the pathways involved.
Listen to Preclinical cell based assays.
[ Top ]
Human Collagen Type I ELISA
Collagen Type I is the most abundant protein and is found in the skin, connective tissue, tendon, ligaments, cornea, intevertebral disks and bone. It has been found to be involved in many human diseases such as fibrosis, osteoporosis, cancer and artherosclerosis.
The human collagen Type I ELISA provides and easy to use assay to detect and quantify type I collagen in cell culture supernates.
Benefits:
- Pre-coated ready to use plate: eliminates 24 hour plate coating step
- Rapid - get results in under 3 hours
- Easy-to-use: all reagents are included for quick and easy set-up
[ Top ]
Recent Peer Publications
Il-1 Related protein DT2 suppressed the initial stage of bleomycin-induced lung injury.
N Mato. et al., (Feb 2009) Eur Respir J
Product: T1/ST2 Monoclonal Antibody
resolution of Allergic Inflammation and AHR is dependent upon disruption of the T1/ST2-IL-33 Pathway.
Kearley J et al., (Jan 2009) Am J Respir Crit Care Med
Product: T1/ST2 Monoclonal Antibody
Pathophysiological features of asthma develop in parallel in house dust mite exposed neonatal mice.
Saglani S et al., (Jan 2009) Am J Respir Cell Mol Biol
Product: T1/ST2 Monoclonal Antibody
Plasma osteopontin modulates chronic restraint stress-induced thymus atrophy by regulating stress hormones; Inhibition by an anti-osteopontin monoclonal antibody.
kathryn X Wang et al., (Feb 2009) J Immunol 182:2485
Product ACTH ELISA
[ Top ]
Monoclonal antibody (IgM) to keratocan: species specificity.
Keratocan belongs to the Small Leucine Rich Proteoglycan (SLRP) family. It was originally found to be a cornea specific keratan sulphate proteoglycan that, along with lumican, plays a role in the development and maintenance of corneal transparency. Mutations of keratocan cause cornea plana in humans, which is often associated with glaucoma, wherase the absence of lumican leads to formation of cloudy corneas.
MD Biosciences monoclonal antibody to keratocan recognizes a protein core epitope in human bovine, porcine, mouse and chicken tissues. This epitope is best recognized after karatanse and keratanase II treatment/digestion of section (IHC) or tissue extracts (western analyses). In some IHC tissue analyses, chondroitinase treament may also be used as this second enzyme treatment facilitates antibody penetration into the tissue.
Appplications:
Figure 1 (left): Cornea samples from human, bovine and pig are treated with Keratanase and keratanase II prior to electrophoresis. Figure 2 (right): Western Blot using anti-keratocan at a concentration of 0.4 ug/mL.
[ Top ]
Allergic Asthma: tools and strategies for investigating your novel therapies.
Allergic asthma is characterized by reversible airway obstruction, elevated levles of IgE, chronic irway inflammation and airway hyper-responsiveness (AHR). In human asthma, eosinophils and lymphocytes infiltrate the bronchial mucosa. Increased mucus secretion and production of Th2-associated cyteokines such as IL-4, IL-5 and IL-13 are also found.
- IL-4 induces differentiation of CD4 T cells into Th2 cells, induces the proliferation of activated B cells and is the major cytokine involved in B cell class switching to IgE.
- IL-5 is involved in eosinophil activation and also facilitates B cell growth and antibody production.
- In addition to inducing IgE prodiction, IL-13 can induce AHR, goblet cell metaplasia and airway glycoprotein hypersecretion, which all contribute to airway obstruction.
Tools for asthma research:
OVA-IgE ELISA
Rat anti-mouse T1/ST2 monoclonal antibody
OVA-Induced Allergic Asthma In vivo model
Lung Fibrosis
LPS lung Inflammation
Passive Cutaneous Anaphylaxis (PCA)
[ Top ]